Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

Investor News

Not intended for U.S. and UK Media

Nexavar Data in Multiple Tumor Types To Be Presented at 2011 American Society of Clinical Oncology Annual Meeting (ASCO)

Leverkusen, May 18, 2011 – Bayer HealthCare and Onyx Pharmaceuticals, Inc. today announced that studies evaluating the use of Nexavar® (sorafenib) tablets will be presented at the 2011 American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

“Bayer and Onyx remain committed to researching the potential utility of Nexavar, and the number of abstracts being presented at this year’s ASCO is a true testament to this commitment,” said Dr. Dimitris Voliotis, Vice President, Global Clinical Development Oncology, Bayer HealthCare. “The companies look forward to continuing to work together, and with various institutions and study groups, to further explore Nexavar. Nexavar has demonstrated efficacy in patients with unresectable liver cancer and advanced kidney cancer, and we remain committed to determine the potential of this therapy for patients.”

Bayer and Onyx-sponsored studies evaluating Nexavar being presented at ASCO include:

GIDEON (Global investigation of Therapeutic Decisions in Hepatocellular Carcinoma [HCC] And Of Its Treatment with Sorafenib) 2nd interim analysis in more than 1500 Patients: clinical findings in patients with liver dysfunction

- Jorge Marrero, M.D., Associate Professor, Department of Internal Medicine, University of Michigan
- Abstract number: 4001
- June 7, 9:45 am, Oral abstract session

Efficacy and safety of intra-patient dose escalation of sorafenib as first-line treatment for metastatic renal cell carcinoma (mRCC)

- Professor Martin Gore, Medical Director, The Royal Marsden and Professor of Cancer Medicine at The Institute of Cancer Research, United Kingdom
- Abstract number: 4609
- June 5, 8:00 am – 12:00 pm, General Poster Session

Sorafenib plus chemotherapy for patients with advanced breast cancer previously treated with bevacizumab.

- Clifford Hudis, M.D., Memorial Sloan-Kettering Cancer Center
- Abstract number: 1009
- June 6, 11:45 am, Oral Abstract Session

Design of RESILIENCE: A phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer.

- Jose Baselga, M.D., Ph.D., Massachusetts General Hospital
- Abstract number: TPS123
- June 6, 8:00 am – 12:00 pm, Trials in Progress Poster Session

Development and validation of a prediction tool for hand-foot skin reaction (HFSR) in patients receiving sorafenib

- Jian Yu, M.D., University of Pittsburgh Cancer Institute
- Abstract number: 2605
- June 6, 8:00 am – 12:00 pm, General Poster Session

Additional company- and investigator-sponsored studies evaluating Nexavar in a variety of tumor types including lung cancer, thyroid cancer and ovarian cancer will also be presented at ASCO.

About Nexavar®

Nexavar®, an oral anti-cancer therapy, is currently approved in more than 100 countries for liver cancer where it remains the only approved systemic agent proven to extend survival and in 100 countries for the treatment of patients with advanced kidney cancer. In Europe, Nexavar is approved for the treatment of hepatocellular carcinoma (HCC) and for the treatment of patients with advanced renal cell carcinoma (RCC) who have failed prior

interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Nexavar inhibits processes involved in both the tumor cell and tumor vasculature. In preclinical studies, Nexavar has been shown to target members of two classes of kinases known to be involved in both cell proliferation (growth) and angiogenesis (blood supply) – two important processes that enable cancer growth. These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR B, KIT, FLT-3 and RET.

Nexavar is also being evaluated by the companies, international study groups, government agencies and individual investigators as a single agent or combination treatment in a range of cancers, including lung, thyroid, ovarian and colorectal cancer and as an adjuvant therapy for liver and kidney cancer.

About Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a selective proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, an alpha-folate receptor targeted inhibitor of thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 16.913 billion (2010), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2010) and is

represented in more than 100 countries. Find more information at www.bayerhealthcare.com.

Find more information at www.bayerpharma.com.

Bayer AG, Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)
Dr. Juergen Beunink (+49-214-30-65742)
Peter Dahlhoff (+49-214-30-33022)
Judith Nestmann (+49-214-30-66836)
Dr. Olaf Weber (+49-214-30-33567)
Fabian Klingen (+49-214-30-35426)
Ute Menke (+49-214-30-33021)

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by the Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.